Mereo BioPharma has appointed Wills Hughes-Wilson as Head of Patient Access and Commercial Planning. Most recently, Wills served on the Executive Leadership Team as Chief Patient Access Officer and Senior Vice President Access & External Affairs at Swedish Orphan Biovitrum (Sobi), an international specialty healthcare company dedicated to rare diseases. Prior to joining Sobi, she served as Vice President of Health and Market Access Policy at Genzyme Corporation (now part of Sanofi).